Sorafenib/Capecitabine Combo Boosts Progression-Free Survival In Advanced Breast Canc
 

BERLIN - The potent oral multiple kinase inhibitor sorafenib (NexavarR) combined with the chemotherapy drug capecitabine (XelodaR) significantly improves progression-free survival (PFS) over capecitabine alone in patients with locally advanced or metastatic HER-2 negative breast cancer, according to phase 2b results released at the joint 15th European Cancer Organization (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress.

More...